SRSF1 and acute myeloid leukemia: Notably, some of the differentially expressed genes following GSK-J4 treatment were also enriched in RNA splicing and spliceosome, such as SF3B5 and SRSF1 (data not shown), suggesting that the mechanisms underlying GSK-J4 mediated effects on AML cells may be more complex.